SCHEMBL21878045

SCHEMBL21878045

CC(=O)OCC(=O)Nc1c(Cl)ncnc1NCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
EGFR P00533 2/20 0.34
KDM4E B2RXH2 3/20 0.34
RECQL P46063 2/20 0.34
ALDH1A1 P00352 3/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
VCP P55072 1/20 0.33
MEN1 O00255 1/20 0.33
GBA1 P04062 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.32
NR4A1 P22736 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359033 0.77 HPGD (0.40) SMN1; SMN2HPGDMAPTRAB9ANPC1
SCHEMBL21878156 0.76 ADORA3 (0.39) SMN1; SMN2RAB9ANPC1EGFRALDH1A1
SCHEMBL21877955 0.75 HTT (0.40) SMN1; SMN2MAPTRAB9ANPC1EGFR
SCHEMBL26604369 0.71 LMNA (0.39) SMN1; SMN2MAPTKDM4EALDH1A1KMT2A
SCHEMBL31268616 0.71 LMNA (0.39) SMN1; SMN2MAPTKDM4EALDH1A1KMT2A
SCHEMBL25328099 0.70 ALDH1A1 (0.42) SMN1; SMN2KDM4ERECQLALDH1A1
SCHEMBL30662847 0.69 LMNA (0.36) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL26604519 0.69 LMNA (0.36) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL30662894 0.69 LMNA (0.34) SMN1; SMN2MAPTEGFRKDM4EALDH1A1
SCHEMBL26604498 0.69 LMNA (0.34) SMN1; SMN2MAPTEGFRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873484-B1 NOVEL STING AGONISTS VENENUM BIODESIGN LLC (US) 2023-08-23 EP disclosed
US-20220048936-A1 NOVEL STING AGONISTS Venenum Biodesign, LLC (US) 2022-02-17 US disclosed
US-11161864-B2 Sting agonists Venenum Biodesign, LLC (US) 2021-11-02 US disclosed
US-20200131209-A1 NOVEL STING AGONISTS Venenum Biodesign, LLC 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131209-A1 NOVEL STING AGONISTS STING1, CGAS, TBK1 SMN1; SMN2 1607/4885HPGD 3904/4885MAPT 1481/4885
US-11161864-B2 Sting agonists STING1, IRF3, CGAS SMN1; SMN2 1544/4885HPGD 3917/4885MAPT 1440/4885
US-20220048936-A1 NOVEL STING AGONISTS STING1, IRF3, CGAS SMN1; SMN2 1613/4885HPGD 3887/4885MAPT 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.